剂型：注射剂 规格：16.7ml：0.3g 申请事项：药品注册（境内生产） 证券代码：600267 证券简称：海正药业 公告编号：临 2025-18 号 浙江海正药业股份有限公司 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江海正药业股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的泊沙康唑注射液《药品注册证书》。 现就相关情况公告如下： 一、药品基本情况 药品名称：泊沙康唑注射液 注册分类：化学药品 4 类 处方药/非处方药：处方药 受理号：CYHS2302492 证书编号：2025S00983 药品批准文号：国药准字 H20253842 药品批准文号有效期：至 2030 年 04 月 07 日 上市许可持有人、生产企业：浙江海正药业股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、该药品其他相关情况 泊沙康唑注射液为医保目录乙类药物，用于 13 岁和 1 ...

创新药概念震荡拉升，海南海药（000566）涨停，一品红（300723）、泓博医药（301230）、科兴制 药、海正药业（600267）、中源协和（600645）等跟涨。 暗盘资金正涌入这些股票，点击速看>>> ...

Group 1 - The company will hold its 2024 Annual General Meeting on April 18, 2025 [2][3] - The meeting will utilize a combination of on-site and online voting methods [4][5] - The voting will take place on the same day as the meeting, with specific time slots for online voting [5][10] Group 2 - The meeting will be convened by the Board of Directors, approved in the 35th meeting of the 9th Board [3] - The agenda includes the review of the Independent Directors' 2024 Annual Work Report [8] - There are 14 special resolution proposals and 9 proposals requiring separate voting for minority shareholders [9] Group 3 - Shareholders must register to attend the meeting, with specific documentation required for both individual and corporate shareholders [12][15] - The registration period is set for April 15, 2025 [15] - The company will provide a reminder service for shareholders to ensure participation [16]

证券代码：600267 证券简称：海正药业 公告编号：临 2025-17 号 浙江海正药业股份有限公司 关于召开 2024 年年度股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江海正药业股份有限公司（以下简称"公司"）于2025年3月29日在《中 国证券报》《上海证券报》《证券时报》和上海证券交易所网站（www.sse.com.cn） 上刊登了《浙江海正药业股份有限公司关于召开2024年年度股东大会的通知》（公 告编号：临2025-15号）。本次股东大会采用现场和网络投票相结合的方式召开， 现发布本次股东大会提示性公告。 一、 召开会议的基本情况 (一)股东大会类型和届次 2024 年年度股东大会 召开的日期时间：2025 年 4 月 18 日 13 点 00 分 召开地点：浙江海正药业股份有限公司会议室（台州市椒江区外沙路 46 号） (五)网络投票的系统、起止日期和投票时间。 (二)股东大会召集人：董事会，经第九届董事会第三十五次会议审议通过，决定 召开。 (三)投票方式：本次股东 ...

会议议程 时间：2025 年 4 月 18 日（周五）下午 13：00，会期半天 浙江海正药业股份有限公司 2024 年年度股东大会会议资料 浙江海正药业股份有限公司 2024 年年度股东大会会议资料 二○二五年四月十八日 浙江海正药业股份有限公司 2024 年年度股东大会会议资料 地点：浙江海正药业股份有限公司（以下简称"公司"）会议室（台州市椒江区外沙 路 46 号） 主要议程： 一、宣布大会开始并宣布到会代表资格审查结果 二、审议下列议案 | 序号 | 议案名称 | | --- | --- | | 非累积投票议案 | | | 1 | 2024 年度董事会工作报告 | | 2 | 2024 年度监事会工作报告 | | 3 | 年年度报告及摘要 2024 | | 4 | 2024 年度财务决算报告和 2025 年度财务预算报告 | | 5 | 2024 年度利润分配预案 | | 6 | 关于申请银行借款综合授信额度的议案 | | 7 | 关于开展外汇套期保值业务的议案 | | 8 | 关于利用自有闲置资金购买理财产品的议案 | | 9 | 关于公司董事 2024 年度薪酬的议案 | | 10 | 关于公司监 ...

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. reported a record high net profit of 601 million yuan for the fiscal year 2024, driven by effective promotion of formulation products and growth in the pharmaceutical raw materials business [3][4]. Financial Performance - The company achieved an operating income of 9.787 billion yuan, with a net profit attributable to shareholders of 601 million yuan, marking a turnaround from previous losses [3]. - The non-recurring net profit was 423 million yuan, also reflecting a significant improvement [3]. - The company plans to distribute a cash dividend of 2.10 yuan per 10 shares and has repurchased shares worth approximately 96.4589 million yuan, totaling 342 million yuan, which is 56.87% of the net profit [3]. Strategic Adjustments - Haizheng Pharmaceutical adopted a "sales first, profit returned" strategy, leading to improved operational efficiency and a reduction in sales expense ratio, accounts receivable, and inventory [4]. - The net cash flow from operating activities increased by 40.72% to 2.115 billion yuan, and the debt-to-asset ratio decreased by 12% to 46.29% [4]. Business Segments - The pharmaceutical formulation business saw a revenue increase of 6.8% to 5.22 billion yuan, solidifying its position in key therapeutic areas [4]. - The raw materials business revenue grew by 18% to 1.23 billion yuan, while the animal health segment expanded with several new drug launches [4]. Innovation and Development - The company is actively exploring new business areas such as health, medical aesthetics, and CXO, with plans for regenerative medical formulations expected to enter clinical registration by 2026 [5]. - Haizheng Pharmaceutical has made significant progress in e-commerce, with substantial growth in key products and pet business sales [5]. - The company has restructured its R&D resources, resulting in enhanced research efficiency and the establishment of advanced R&D platforms, with 10 drug registration approvals and 62 patent applications in the year [5]. Future Outlook - The company anticipates that 2025 will be a pivotal year for significant development and aims to strengthen its core business while exploring new growth areas [6].

同天，海正药业首次发布2024年度可持续发展报告替代社会责任报告，全面展示了公司2024年积极承担 社会、环境、治理责任的活动及表现，持续推动公司可持续发展。据悉，凭借可持续发展方面的优异表 现，2025年初，海正药业获得了EcoVadis铜牌认可。 聚焦变革转型，为持续增长奠基 2024年，海正药业提出"销售为先，利润归仓"策略，推进一体化管理，运营效率明显改善，销售费用 率、应收账款和存货等方面的指标均有改善；2024年扣除医药经销业务部分后，营业收入增长8%，经 营活动产生的现金流量净额同比增长40.72%至21.15亿元，资产负债率46.29%，同比下降12.00%，业务 逐步往良性态势发展，凸显出公司战略调整的成效。 海正药业通过系列变革与转型，推动各板块业务持续健康发展。医药制剂业务(包含CSO)营收增长显 著，同比增长6.8%至52.2亿元，综合实力上升，公司在IQVIA中国药企权威榜单的排名跃升12位至第26 位，并在降脂、抗感染与激素3个关键赛道领域巩固标杆地位，彰显头部优势。重点产品赛斯美2024年 销量625.69万盒，同比增加31%，赛斯美品牌通过"医学科普视频矩阵项目"与"海心汇"心 ...

根据市场公开信息及4月1日披露的机构调研信息，知名私募高毅资产近期对3家上市公司进行了调研， 相关名单如下： 1）良信股份 （上海高毅资产管理合伙企业(有限合伙)参与公司分析师会议） 调研纪要：2024年度，伟星股份钮扣和拉链业务营收实现不错增长，拉链业务同比增长16%，钮扣业务 同比增长22%。公司2025年奋斗目标为实现营业收入50.00亿元，致力于成为全球化、创新型的时尚辅 料王国。越南工业园2024年3月底投产，订单总量不足导致亏损，预计2025年营业收入将显著提升。国 内业务营收30.94亿元，同比增长14.74%；国际业务营收15.81亿元，同比增长30.62%。2024年度综合产 能利用率为68.82%，同比提升2.01个百分点。公司注重"产品+服务"，在产品多样性、时尚性、创新能 力等方面形成竞争优势。织带品类规模小，前期固定投入大，短期亏损，未来将逐步向好。直接出口美 国占比低，终端消费国或区域调整关税对公司业务直接影响有限。公司尚未有实质性股权激励规划，会 合理制定年度利润分配方案，近两年资本开支主要与募投项目相关。 机构简介： 上海高毅资产管理合伙企业（有限合伙）是国内投研实力较强、管理 ...

Core Viewpoint - Haizheng Pharmaceutical reported a revenue of 9.787 billion yuan for 2024, with a net profit of 601 million yuan, marking a return to profitability compared to the previous year [1][3] Financial Performance - The company's total revenue decreased by 5.65% year-on-year, primarily due to a decline in the pharmaceutical distribution segment [2] - The pharmaceutical manufacturing segment generated 6.045 billion yuan, an increase of 3.63 billion yuan year-on-year, while the pharmaceutical distribution segment saw a revenue of 3.51 billion yuan, down 9.32% [2] - Excluding the pharmaceutical distribution business, Haizheng's revenue would have been 7.1 billion yuan, reflecting an 8% year-on-year growth [2] - The net profit attributable to shareholders was 601 million yuan, with a non-GAAP net profit of 423 million yuan, an increase of 523 million yuan year-on-year [3] Business Segments - The pharmaceutical formulation segment achieved a revenue of 4.411 billion yuan, up 1.71 billion yuan year-on-year, while the raw material drug segment generated 1.229 billion yuan, an increase of 1.85 billion yuan [2][3] - Haizheng Pharmaceutical is actively expanding into emerging markets such as health care, medical aesthetics, and CXO services [2][3] Market Position and Strategy - The company ranks 26th among Chinese pharmaceutical companies according to IQVIA, with notable positions in key therapeutic areas: 4th in lipid-lowering, 9th in anti-infection, and 2nd in hormones [2] - Haizheng is focusing on international market expansion, exporting raw material products to over 70 countries and regions, with more than 400 overseas clients, including top global pharmaceutical companies [4][5] Research and Development - The company has initiated a 170 million yuan synthetic biology flexible production line project and has over ten products in the pipeline for orthopedic calcium supplementation, liver protection, and medical aesthetics [3][5] - R&D expenses for 2024 are projected at 358 million yuan, a decrease of 34 million yuan year-on-year, but total R&D investment increased to 416 million yuan [5] - Haizheng has established a new drug research center in Shanghai and is developing advanced R&D platforms in areas such as small nucleic acids and complex formulations [5] Compliance and Regulatory Environment - The pharmaceutical industry is facing increasing regulatory scrutiny, with plans to complete a comprehensive compliance system upgrade by 2025 [6]

Business Performance by Sector - The pharmaceutical manufacturing sector reported revenue of approximately 6.05 billion, with a gross margin of 60.35% [1] - The pharmaceutical commercial sector generated revenue of about 3.51 billion, but experienced a significant decline in gross margin to 19.41% [1] - The CMO/CDMO/CRO business had revenue of approximately 7.96 million, with a gross margin of 58.73%, but saw a drastic decrease in performance [1] - Other business segments reported revenue of around 8.93 million, with a gross margin of 48.11% [1] - Overall, the subtotal for all sectors was approximately 9.57 billion in revenue, with a gross margin of 45.33% [1] Strategic Initiatives - The company successfully transitioned from a general agent to a provincial agent, exceeding annual targets and reshaping its business structure [2] - The pharmaceutical e-commerce business achieved significant growth through targeted marketing and expansion into lower-tier markets, with key products showing substantial year-on-year increases [2] - The export formulation business launched three new products in the U.S., achieving profitability in the first year and signing exclusive agreements with three major pharmaceutical companies [2] - The company strengthened its relationships with major clients in the pharmaceutical raw materials sector, leading to stable revenue growth [2] Animal Health Business - The company optimized its sales strategy for economic animal health products, enhancing collaboration with group clients and increasing control over end customers [3] - The integration of the pig health drug and vaccine teams has led to the promotion of a comprehensive "prevention + treatment" solution [3] - The company successfully launched four major new drugs and five new veterinary drugs during the reporting period, with a strong pipeline in domestic markets [3] - The company is actively expanding into international markets, with five international registration submissions completed [3]